Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tvardi Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Tvardi Therapeutics, Inc.

TVRD

Tvardi Therapeutics, Inc.

About Tvardi Therapeutics, Inc.

Cara Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for chronic pruritus. Its lead product, difelikefalin, is approved for treating pruritus associated with advanced chronic kidney disease in multiple countries. The company engages in licensing, collaboration, and royalty arrangements, with a business model centered on drug development, strategic partnerships, and out-licensing to maximize global reach and shareholder value.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tvardi Therapeutics, Inc.

1
1
Tvardi Therapeutics, Inc. Tvardi Therapeutics Reports 2025 Financial Results and Business Update

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
Tvardi Therapeutics, Inc. Tvardi Therapeutics Reports $2.57 Million Revenue in Q1 2025, Driven by Collaborative Revenue Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Tvardi Therapeutics, Inc. Cara Therapeutics Reports $70.9 Million Net Loss for 2024, Revenue Declines to $7.1 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Tvardi Therapeutics, Inc. Cara Therapeutics Reports Significant Financial Challenges, Decline in Revenue and Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments